These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 34554395)

  • 1. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach.
    Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK
    Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Das SK; Deka SJ; Paul D; Gupta DD; Das TJ; Maravi DK; Tag H; Hui PK
    J Biomol Struct Dyn; 2022 Sep; 40(15):6857-6867. PubMed ID: 33625319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of phytocompounds from Houttuynia cordata Thunb. as potential inhibitors for SARS-CoV-2 replication proteins through GC-MS/LC-MS characterization, molecular docking and molecular dynamics simulation.
    Das SK; Mahanta S; Tanti B; Tag H; Hui PK
    Mol Divers; 2022 Feb; 26(1):365-388. PubMed ID: 33961167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer.
    Kalirajan R; Pandiselvi A; Gowramma B; Balachandran P
    Curr Drug Res Rev; 2019; 11(2):118-128. PubMed ID: 31513003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
    Rathi E; Kumar A; Kini SG
    J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer - An in-silico approach.
    Rajagopal K; Sri VB; Byran G; Gomathi S
    Curr Drug Res Rev; 2022; 14(1):61-72. PubMed ID: 34139975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
    Sangande F; Julianti E; Tjahjono DH
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical Characterization,
    Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
    Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potential HER2 inhibitors from
    Balogun TA; Iqbal MN; Saibu OA; Akintubosun MO; Lateef OM; Nneka UC; Abdullateef OT; Omoboyowa DA
    J Biomol Struct Dyn; 2022; 40(23):12772-12784. PubMed ID: 34514973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of luteolin -7-glucoside and epicatechin gallate from
    Maiti P; Nand M; Joshi T; Ramakrishnan MA; Chandra S
    J Biomol Struct Dyn; 2021 Sep; 39(14):5048-5057. PubMed ID: 32579072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular docking and dynamic simulation to identify potential phytocompound inhibitors for EGFR and HER2 as anti-breast cancer agents.
    Prabhavathi H; Dasegowda KR; Renukananda KH; Karunakar P; Lingaraju K; Raja Naika H
    J Biomol Struct Dyn; 2022 Jul; 40(10):4713-4724. PubMed ID: 33345701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity.
    Alsamarah A; LaCuran AE; Oelschlaeger P; Hao J; Luo Y
    PLoS One; 2015; 10(7):e0132221. PubMed ID: 26133550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of
    Babu TM; Rammohan A; Baki VB; Devi S; Gunasekar D; Rajendra W
    Drug Des Devel Ther; 2016; 10():3611-3632. PubMed ID: 27853354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing an ensemble docking-based virtual screening strategy for kinase targets by considering protein flexibility.
    Tian S; Sun H; Pan P; Li D; Zhen X; Li Y; Hou T
    J Chem Inf Model; 2014 Oct; 54(10):2664-79. PubMed ID: 25233367
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Maruthanila VL; Elancheran R; Mirunalini S
    Curr Comput Aided Drug Des; 2022; 18(3):196-212. PubMed ID: 35598239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in structure-based drug design and virtual screening of VEGFR tyrosine kinase inhibitors.
    Hoi PM; Li S; Vong CT; Tseng HH; Kwan YW; Lee SM
    Methods; 2015 Jan; 71():85-91. PubMed ID: 25239735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D pharmacophore-based virtual screening, docking and density functional theory approach towards the discovery of novel human epidermal growth factor receptor-2 (HER2) inhibitors.
    Gogoi D; Baruah VJ; Chaliha AK; Kakoti BB; Sarma D; Buragohain AK
    J Theor Biol; 2016 Dec; 411():68-80. PubMed ID: 27693363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of potential edible spices as EGFR and EGFR mutant T790M/L858R inhibitors by structure-based virtual screening and molecular dynamics.
    Ahmad Ansari I; Debnath B; Kar S; Patel HM; Debnath S; Zaki MEA; Pal P
    J Biomol Struct Dyn; 2024 Mar; 42(5):2464-2481. PubMed ID: 37349948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of HER2 inhibitors from curcumin derivatives using combination of
    Saibu OA; Singh G; Olugbodi SA; Oluwafemi AT; Ajayi TM; Hammed SO; Oladipo OO; Odunitan TT; Omoboyowa DA
    J Biomol Struct Dyn; 2023; 41(21):12328-12337. PubMed ID: 36752338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.